ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

06 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

25 May 2023 17:38:38 By Nasdaq GlobeNewswire

Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations

23 May 2023 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

10 May 2023 07:00:01 By Nasdaq GlobeNewswire

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting

26 Apr 2023 10:00:11 By Nasdaq GlobeNewswire

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

17 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2023 17:00:41 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

01 Feb 2023 07:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2023 17:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2022 17:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

09 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

08 Nov 2022 07:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2022 17:38:22 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

24 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

17 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2022 17:32:42 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer

27 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer

19 Sep 2022 07:00:00 By Nasdaq GlobeNewswire